Anzeige
Mehr »
Sonntag, 15.03.2026 - Börsentäglich über 12.000 News
Insider kaufen kräftig zu - 421.670 CAD an Käufen, während Silber $88 erreicht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 883035 | ISIN: US8816242098 | Ticker-Symbol: TEV
Tradegate
13.03.26 | 21:20
24,800 Euro
-0,80 % -0,200
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
5-Tage-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
25,00025,20014.03.
24,80025,20013.03.

Aktuelle News zur TEVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSkyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales34
MoTeva Pharm stellt auf Leerink-Konferenz neue Wachstumsstrategie vor34
08.03.Teva CEO cashes in $30 million in shares in two weeks42
TEVA Aktie jetzt für 0€ handeln
04.03.Forget Teva: This Dividend Top Dog Is the Real Value Buy Today56
04.03.Blackstone puts $400M into Teva, Sanofi gut disease drug29
04.03.Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug7
04.03.Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding37
04.03.Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug13
04.03.Teva: Blackstone Life Sciences To Provide $400 Mln To Support Development Of Duvakitug469PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA) and funds managed by Blackstone Life Sciences announced a $400 million strategic funding...
► Artikel lesen
04.03.Teva secures $400 million from Blackstone to advance flagship IBD drug20
03.03.Teva Pharmaceutical Industries Ltd: Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug1.296Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1ADuvakitug is currently in phase 3 clinical studies for ulcerative colitis...
► Artikel lesen
28.02.Here's Why I Won't Touch Teva Pharmaceutical With a 10-Foot Pole26
25.02.SIPTU engaging with Teva over threatened redundancies18
24.02.Teva Pharmaceutical Industries Ltd: Teva to Present at the Upcoming Investor Conferences in March2.259PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will...
► Artikel lesen
23.02.FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application12
21.02.Teva, Medincell granted FDA review for long-acting antipsychotic16
21.02.FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment940PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration...
► Artikel lesen
20.02.FDA akzeptiert Zulassungsantrag von Teva für monatliche Schizophrenie-Behandlung17
20.02.FDA accepts Teva's application for monthly schizophrenia treatment2
20.02.Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults759Olanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help...
► Artikel lesen
Weiter >>
251 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,14